Jacobs & Co’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.2M | Sell |
90,643
-4,932
| -5% | -$413K | 0.7% | 52 |
|
|
2026
Q1 | $7.65M | Sell |
95,575
-4,940
| -5% | -$407K | 0.76% | 55 |
|
|
2025
Q4 | $8.57M | Sell |
100,515
-12,150
| -11% | -$997K | 0.81% | 50 |
|
|
2025
Q3 | $8.76M | Sell |
112,665
-5,647
| -5% | -$441K | 0.84% | 47 |
|
|
2025
Q2 | $9.25M | Sell |
118,312
-7,261
| -6% | -$542K | 0.92% | 45 |
|
|
2025
Q1 | $9.1M | Sell |
125,573
-155
| -0.1% | -$11.1K | 0.97% | 42 |
|
|
2024
Q4 | $9.31M | Buy |
125,728
+2,828
| +2% | +$198K | 0.95% | 42 |
|
|
2024
Q3 | $8.11M | Buy |
122,900
+9,879
| +9% | +$718K | 0.81% | 53 |
|
|
2024
Q2 | $10.4M | Buy |
113,021
+240
| +0.2% | +$21.3K | 1.09% | 38 |
|
|
2024
Q1 | $10.8M | Buy |
112,781
+2,116
| +2% | +$178K | 1.14% | 39 |
|
|
2023
Q4 | $8.44M | Buy |
110,665
+3,447
| +3% | +$240K | 0.96% | 45 |
|
|
2023
Q3 | $7.43M | Buy |
107,218
+3,443
| +3% | +$277K | 0.93% | 48 |
|
|
2023
Q2 | $9.79M | Buy |
103,775
+1,096
| +1% | +$95.3K | 1.16% | 39 |
|
|
2023
Q1 | $8.49M | Buy |
102,679
+933
| +0.9% | +$73.3K | 1.05% | 43 |
|
|
2022
Q4 | $7.59M | Buy |
101,746
+4,397
| +5% | +$339K | 0.99% | 48 |
|
|
2022
Q3 | $8.04M | Buy |
97,349
+812
| +0.8% | +$78.1K | 1.16% | 41 |
|
|
2022
Q2 | $9.18M | Sell |
96,537
-5,930
| -6% | -$614K | 1.23% | 38 |
|
|
2022
Q1 | $12.1M | Sell |
102,467
-2,975
| -3% | -$334K | 1.34% | 29 |
|
|
2021
Q4 | $13.7M | Sell |
105,442
-1,310
| -1% | -$153K | 1.42% | 26 |
|
|
2021
Q3 | $12.1M | Sell |
106,752
-2,376
| -2% | -$271K | 1.39% | 25 |
|
|
2021
Q2 | $11.3M | Sell |
109,128
-4,410
| -4% | -$416K | 1.31% | 28 |
|
|
2021
Q1 | $9.5M | Sell |
113,538
-1,204
| -1% | -$102K | 1.16% | 38 |
|
|
2020
Q4 | $10.5M | Sell |
114,742
-261
| -0.2% | -$21.6K | 1.36% | 26 |
|
|
2020
Q3 | $9.18M | Buy |
115,003
+2,054
| +2% | +$160K | 1.33% | 28 |
|
|
2020
Q2 | $7.8M | Sell |
112,949
-337
| -0.3% | -$23.9K | 1.27% | 29 |
|
|
2020
Q1 | $7.12M | Sell |
113,286
-5,625
| -5% | -$406K | 1.37% | 26 |
|
|
2019
Q4 | $9.25M | Sell |
118,911
-10,407
| -8% | -$813K | 1.4% | 24 |
|
|
2019
Q3 | $9.48M | Sell |
129,318
-3,576
| -3% | -$251K | 1.54% | 22 |
|
|
2019
Q2 | $8.18M | Buy |
132,894
+3,594
| +3% | +$217K | 1.32% | 26 |
|
|
2019
Q1 | $8.25M | Buy |
+129,300
| New | +$7.38M | 1.4% | 26 |
|
|
2016
Q1 | – | Sell |
-78,330
| Closed | -$2.03M | – | 126 |
|
|
2015
Q4 | $2.03M | Sell |
78,330
-8,940
| -10% | -$232K | 0.53% | 69 |
|
|
2015
Q3 | $2.07M | Sell |
87,270
-1,020
| -1% | -$24.6K | 0.55% | 68 |
|
|
2015
Q2 | $2.1M | Sell |
88,290
-3,150
| -3% | -$71.1K | 0.52% | 71 |
|
|
2015
Q1 | $2.17M | Sell |
91,440
-2,550
| -3% | -$57.2K | 0.55% | 68 |
|
|
2014
Q4 | $2M | Buy |
93,990
+3,000
| +3% | +$60.3K | 0.53% | 72 |
|
|
2014
Q3 | $1.55M | Hold |
90,990
| – | – | 0.44% | 75 |
|
|
2014
Q2 | $1.3M | Hold |
90,990
| – | – | 0.38% | 79 |
|
|
2014
Q1 | $1.13M | Buy |
90,990
+3,900
| +4% | +$45K | 0.35% | 79 |
|
|
2013
Q4 | $954K | Buy |
87,090
+12,780
| +17% | +$144K | 0.31% | 85 |
|
|
2013
Q3 | $862K | Buy |
74,310
+2,250
| +3% | +$26.3K | 0.3% | 83 |
|
|
2013
Q2 | $807K | Buy |
+72,060
| New | +$853K | 0.29% | 84 |
|
Other funds holding EW
Jacobs & Co's EW Position: Q2 2026 in Review
Jacobs & Co reduced its Edwards Lifesciences (EW) stake by 5.2% in Q2 2026, selling an estimated $413K and leaving 90,643 shares worth $8.2M. The position accounts for 0.7% of the portfolio, ranked #52.
Jacobs & Co first reported a position in EW in Q2 2013 and has held it in 41 quarters since. The position peaked at $13.7M in Q4 2021. 1,334 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Jacobs & Co held 90,643 shares of Edwards Lifesciences worth $8.2M as of Q2 2026.
- Jacobs & Co sold 4,932 Edwards Lifesciences shares in Q2 2026, an estimated $413K.
- Edwards Lifesciences made up 0.7% of Jacobs & Co's portfolio in Q2 2026, its #52 holding.
- Jacobs & Co first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 41 quarters since.
- Jacobs & Co's Edwards Lifesciences position peaked at $13.7M in Q4 2021.
- 1,334 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Jacobs & Co's 13F filing for Q2 2026, filed 9 Jul 2026.